Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2763357 | 0.98 | — | — | |
| SCHEMBL4682199 | 0.95 | — | — | |
| SCHEMBL6636848 | 0.86 | — | — | |
| SCHEMBL7468947 | 0.82 | HSD11B1 (0.30) | HSD11B1 | |
| SCHEMBL5379373 | 0.82 | EPHX2 (0.35) | — | |
| SCHEMBL7660262 | 0.81 | — | — | |
| SCHEMBL1222251 | 0.74 | HTT (0.39) | — | |
| SCHEMBL16774677 | 0.74 | — | — | |
| Bromide SCHEMBL1222565 | 0.73 | HTT (0.40) | — | |
| SCHEMBL28547186 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119019241-B | Synthesis method of alpha-cyclopentyl mandelic acid | 深圳智微通科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-119019241-A | Synthesis method of alpha-cyclopentyl mandelic acid | 深圳智微通科技有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-118388328-A | Method for synthesizing aldehyde ketone compound through catalyst-free photochemical decarboxylation | 齐鲁工业大学(山东省科学院) | 2024-07-26 | — | — | CN | disclosed |
| CN-114984001-B | Use of glycopyrrolate for the preparation of a medicament for the prevention of nausea and vomiting symptoms | 重庆医科大学附属第二医院 | 2023-06-13 | — | — | CN | disclosed |
| CN-114984001-A | Use of glycopyrrolate for the manufacture of a medicament for the prevention of nausea and vomiting symptoms | 重庆医科大学附属第二医院 | 2022-09-02 | — | — | CN | disclosed |
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-21 | — | — | US | disclosed |
| US-20090176856-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-07-09 | — | — | US | disclosed |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| EP-1546099-B1 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2008-12-31 | — | — | EP | disclosed |
| US-7399779-B2 | 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-07-15 | — | — | US | disclosed |
| EP-1546099-A4 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2006-08-02 | — | — | EP | disclosed |
| US-20060122253-A1 | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-06-08 | — | — | US | disclosed |
| WO-2006054162-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006035303-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006035282-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
| CN-1668585-A | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists | RANBAXY LAB LTD (IN) | 2005-09-14 | — | — | CN | disclosed |
| EP-1546099-A2 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2005-06-29 | — | — | EP | disclosed |
| EP-1546098-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014853-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004004629-A2 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176856-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | HSD11B1 2012/4885 |
| US-20060122253-A1 | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | HSD11B1 896/4885 |
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | HSD11B1 1683/4885 |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | HSD11B1 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.